A comparative clinical trial on the effects of atorvastatin 10mg and atorvastatin 5mg/ ezetimibe 10mg in type 2 diabetic patients with nephropathy and hypercholesterolemia
Not Applicable
- Conditions
- Type 2 diabetic patients with nephropathy and hypercholesterolemia
- Registration Number
- JPRN-UMIN000025620
- Lead Sponsor
- Misaki Naika Clinic
- Brief Summary
Compared with the atorvastatin group, the rate of reduction of non HDL-C and LDL-C was significantly larger in the ezetimibe group. Renal marker and safety did not differ between the two groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with hypersensitivity of the test drugs 2) Patients with hepatic dysfunction(AST or ALT>=100U) 3) Patients with a past history of cerebrovascular or cardiovascular event 4) Patients with secondary or drug-induced hyperlipidemia 5) Patients with familial hypercholesterolemia 6) Pregnant or possibly pregnant patients, patients on lactation 7) Patients with insulin treatment 8) Patients with fibrate treatment 9) Inappropriate patients for this study according to the judgment of Investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method